ストックスクリーナーアプリを入手
40.65
1.29%
-0.53
前日終値:
$41.18
開ける：
$40.58
24時間の取引高:
2.12M
Relative Volume:
0.71
時価総額：
$97.38B
収益：
$49.41B
当期純損益:
$5.59B
株価収益率:
17.03
EPS:
2.3875
ネットキャッシュフロー:
$8.32B
1週間 パフォーマンス:
-4.38%
1か月 パフォーマンス:
-9.30%
6か月 パフォーマンス:
-13.10%
1年 パフォーマンス:
-10.95%
1日の値動き範囲:
$40.40
$40.80
1週間の範囲:
$40.40
$41.96
52週間の値動き範囲:
$40.40
$52.68
Sanofi Adr Stock (SNY) Company Profile
Compare SNY vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
40.64 | 98.51B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
1,184.91 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.86 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
263.50 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.91 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
145.47 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-20 | ダウングレード | BNP Paribas Exane | Outperform → Neutral |
| 2026-02-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2026-01-27 | 開始されました | Citigroup | Neutral |
| 2026-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2026-01-06 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-12-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-12-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-09-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-08-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-03-21 | 開始されました | Goldman | Neutral |
| 2025-01-30 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-07-26 | 繰り返されました | Argus | Buy |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-05 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-10-30 | ダウングレード | Stifel | Buy → Hold |
| 2023-09-06 | アップグレード | Berenberg | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-28 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-03-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-12-13 | 再開されました | Morgan Stanley | Overweight |
| 2022-08-12 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-08-09 | ダウングレード | UBS | Buy → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-09-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | 開始されました | Deutsche Bank | Sell |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-03-17 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-03-11 | アップグレード | Goldman | Neutral → Buy |
| 2020-02-11 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-01-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-09-20 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | 開始されました | Bernstein | Outperform |
| 2019-08-14 | アップグレード | UBS | Neutral → Buy |
| 2018-12-11 | アップグレード | Jefferies | Hold → Buy |
| 2018-11-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | アップグレード | Citigroup | Neutral → Buy |
| 2018-03-23 | アップグレード | Liberum | Hold → Buy |
| 2018-01-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2017-12-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | アップグレード | Barclays | Underweight → Equal Weight |
| 2017-08-30 | アップグレード | HSBC Securities | Reduce → Hold |
すべてを表示
Sanofi Adr (SNY) 最新ニュース
Sanofi (SNY) stock price, news, quote and history - Yahoo Finance Australia
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.
The Best Healthcare Stocks to Buy - Morningstar
Is Regeneron Stock a Bargain Below $800? - The Motley Fool
DPT Vaccine Market Size Report 2026: Projected to Reach 5,281.80 Million USD, Growing at a CAGR of 0.49% - note.com
Sanofi transfers 20 medicines to Cheplapharm partnership - grafa.com
Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive (NASDAQ:SNY) - Seeking Alpha
Sanofi stock edges higher as Deutsche Bank reiterates Buy rating - AD HOC NEWS
Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID - Finviz
RBC Capital initiates Sanofi stock at Sector Perform on transition risks - Investing.com Canada
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Sanofi ADSADR Key Financial Ratios – Valuation, Profitability & More - Value Research
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability - ChartMill
Sanofi stock holds firm as workforce shake-up follows strong Q2 2026 - ad-hoc-news.de
Sanofi stock steadies after strong Q2 2026 and upgraded guidance - Ad-hoc-news.de
Sanofi stock steadies as upgraded 2026 guidance follows strong Q2 momentum - AD HOC NEWS
European ADRs Drift Lower In US Trading - Finimize
Sanofi stock climbs as MenQuadfi approval and cuts reshape the story - Ad-hoc-news.de
Sanofi stock edges higher as MenQuadfi approval and workforce reshaping define mid-August story - Ad-hoc-news.de
Sanofi's New Leadership Faces Looming Patent Cliff - Morningstar
6 Undervalued Stocks That Crushed Earnings - Morningstar
Resilient Sanofi stock edges higher as Q2 2026 growth and R&D reshuffle shape outlook - Ad-hoc-news.de
Sanofi stock holds steady as India unit boosts profit and secures tax refund - Ad-hoc-news.de
Trump considers order on autism and vaccines: which stocks are most exposed? - Investing.com
Nurix earns $10m milestone as Sanofi starts STAT6 degrader trial - Investing.com Nigeria
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
Key facts: Sanofi SA Sponsored ADR files H1 2026; halts three drugs - TradingView
What's behind Sanofi's latest 5.4% stock pullback? - tradersunion.com
European ADRs Jump In US Trading As Banks Lead - Finimize
SNY Stock Quote Price and Forecast - CNN
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings - Sahm
Ericsson Stock Slumps As ADR Underperformance Weighs On Traders - StocksToTrade
SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile - ChartMill
Sanofi Adr (SNY) 財務データ
収益
当期純利益
現金流量
EPS
0.45%
0.76%
大文字化:
|
ボリューム (24 時間):